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INTRODUCTION
Although synthetic histone deacety-
lases inhibitors (HDACi) hyperacetylate
histones via the conserved N-terminal
lysines present on histones, they also hy-
peracetylate cytoplasmic proteins, in-
cluding transcription factors. Therefore,
unraveling chromatin and thus permit-
ting transcription factors to bind to DNA
is a prominent property of HDACi, but
not their only mechanism of action.
Thus, the ability of HDACi to acetylate
cytoplasmic proteins may affect cellular
functions independent of their role on
gene expression. In humans, there are 18
distinct HDACs (1) and their specific
targeting with synthetic HDACi may
have a role in treating diseases, particu-
larly in chronic diseases such as degen-
erative joint diseases. Also, in order to
be used during chronic disease states,
such as occurs with inflamed joints,
HDACi need to be safe for long-term
use.
Inhibitors of HDAC are used widely in
medicine. For example, valproic acid is
used chronically to treat epilepsy and ob-
sessive disorders (2,3). Whereas several
synthetic inhibitors of HDACs have been
developed to bring about terminal differ-
entiation of cancer cells and to increase
proapoptotic genes (4), to our knowledge
the only HDACi used in humans as an
antiinflammatory agent is ITF2357 (givi-
nostat) (14). ITF2357, a Class I and II
HDACs inhibitor (14), was given to chil-
dren with systemic onset juvenile idio-
pathic arthritis (SOJIA) at a dose of
1.5 mg/ kg for 12 weeks. The study ex-
hibited no organ toxicity and achieved
significant reduction in parameters of
systemic disease but particularly the
number of painful joints (5).
In general, micromolar concentrations
of synthetic HDAC inhibitors are re-
quired to increase the expression of sev-
eral proapoptotic genes in malignant
cells (4,6–8). However, HDACi also
 exhibit immunosuppressive and anti -
inflammatory properties at lower con-
centrations (9). For instance, nanomolar
concentrations of ITF2357 are sufficient
to reduce the production and/or activity
of proinflammatory cytokines in vitro or
to exert a potent effect in animal models
of inflammatory and autoimmune dis-
eases (9–17). Other HDACi, such as
SAHA, share with ITF2357 many of the
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antiinflammatory properties in models of
disease in experimental animals (12,14).
In the present study, we have evalu-
ated the effect of ITF2357 in several mod-
els of arthritis, ranging from acute to
chronic models of arthritis. In addition,
the effect of ITF2357 was studied on both
TNFα- and IL-1β-induced bone
 resorption.
HDAC INHIBITORS DECREASE
CYTOKINE PRODUCTION BY RA
SYNOVIAL CELLS AND RA TISSUE
EXPLANTS
Recently, it was demonstrated that
HDAC expression and activity in synovial
tissue of RA patients correlates positively
with the concentration of TNFα (18). In
addition, it was shown that HDAC in-
hibitors suppress cytokine production by
RA synovial tissue explants and that both
TNFα- and LPS- induced cytokine and
chemokine production were decreased by
inhibition of HDAC activity (19). How-
ever, HDAC inhibition did not influence
the spontaneous cytokine production of
RA synovial macrophages or intact syn-
ovial tissue explants. Interestingly, HDACi
induced apoptosis in RA synovial
macrophages by suppressing antiapop-
totic Bfl-1 protein (19). It has been reported
that HDACi activate either the extrinsic or
the intrinsic death pathway or both of
these pathways (20). In addition, it was
demonstrated that HDACi induce growth
arrest in RA synovial fibroblasts through
induction of p21 and suppression of NF-
κB nuclear accumulation (21). HDACi
suppress cytokine production without an
effect on cell death, which is of high inter-
est. This indicates that it might be possible
to uncouple inhibition of cytokine produc-
tion and induction of apoptosis (14).
INHIBITION OF HDAC ACTIVITY
SUPPRESSES EXPERIMENTAL ARTHRITIS
Since it was demonstrated that HDACi
suppress the production of proinflamma-
tory cytokines, several studies have been
performed to investigate their anti -
inflammatory properties in models of
arthritis. Anti-type II collagen antibody-
induced arthritis (CAIA) is based on the
formation of immune complexes in the
joints of susceptible mice. The onset of
this experimental model of arthritis is
highly dependent on cytokines, such as
TNFα and IL-1. Both prophylactic and
therapeutic treatment of CAIA with
HDACi (TSA or FK228) suppressed
arthritis severity (22,23) and reduced joint
pathology. Of interest, enzymes that pro-
mote joint destruction such as matrix
 metalloproteinases (MMP)-3 and MMP-13
were reduced compared with vehicle. It
is known that these MMPs are induced
by TNFα but predominantly IL-1β.
HDAC inhibition will lead to suppres-
sion of these cytokines and the resultant
reduction of MMP expression or activity
can account for the benefit of HDACi in
models of rheumatoid arthritis.
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Figure 1. Effect of HDACi ITF2357 on SWC-induced arthritis. (A,B) Joint inflammation was in-
duced by injection of 25 μg SCW fragments into the right knee joint of C57/Bl6 mice 2 h
after ITF2357 was orally supplied (n = 5 mice per group). Joint swelling was determined by
99mTc-uptake method (30) at day 1 (A) and day 2 (B). Mice were treated with vehicle, 
1 and 10 mg/kg ITF2357. Note the suppression of joint swelling at day 2 by both 1 and 
10 mg/kg ITF2357. (C) At day 2 chondrocyte proteoglycan (PG)-synthesis was analyzed
by using 35S-sulphate incorporation method (31). Treatment with ITF2357 (10 mg/kg/day)
almost  restored (–13%) the chondrocyte PG-synthesis when compared with vehicle
(–44%). (D) Vehicle treatment showed clear cell influx (predominantly PMNs) in the joint
cavity and synovial lining layer (see arrows). After treatment with 10 mg/kg ITF2357, re-
duced cell influx in the joint cavity was seen. P = patella, F = femur, JC joint cavity. Mann-
Whitney U test was used for statistical analysis. *P < 0.05.
Inhibition of HDAC activity by ITF2357
modulates several in vivo models of in-
flammation, such as LPS- induced shock,
Con A–induced hepatitis, DSS colitis and
even traumatic brain injury (24,14,25). In
these models, it was demonstrated that IL-1
production is reduced after treatment with
ITF2357. IL-1 is the classical proinflamma-
tory cytokine that drives cartilage destruc-
tion during chronic joint inflammation. Of
interest, in the beginning of the cytokine
era, IL-1 was also named by Jeremy Saklat-
vala “catabolin,” referring to its potent
 cartilage destructive properties (26).
Thereafter, it was demonstrated that IL-1
contributes to joint inflammation and se-
vere cartilage destruction (27). IL-1 exerts
potent arthritogenic activity when injected
directly into murine knee joints, whereas
TNFα induces joint swelling and influx of
cells into the joint space (28). Cartilage ex-
posure to IL-1, both in vitro and in vivo, in-
hibits matrix proteoglycan synthesis and
promotes cartilage destruction by upregu-
lation of matrix MMPs. Irreversible carti-
lage damage elicited by MMPs is one of the
hallmarks of joint destruction in inflamma-
tory arthritis. The role of IL-1 was under-
lined further by elegant studies using IL-1
deficient mice. They revealed that IL-1β is
the pivotal mediator that directs chronic
joint inflammation, but both IL-1α and 
IL-1β promote cartilage damage (29,30).
PROTECTIVE EFFECT OF ITF2357 ON
ACUTE JOINT INFLAMMATION AND
CARTILAGE CATABOLISM
The effects of ITF2357 on cartilage ca-
tabolism were studied in a mouse model
of Streptococcus pyogenes cell wall (SCW)-
induced arthritis (31). This is a predomi-
nantly macrophage-driven arthritis
model, initiated by TLR2 and NOD2 trig-
gering (32). The study was performed in a
prophylactic fashion in which the com-
pound was administered orally before an
intraarticular injection of 25 μg SCW frag-
ments (30–32). ITF2357 was given orally
at 1 and 10 mg/kg at –2 hours, 6 hours,
day 1 and day 2. Treatment with 1 and
10 mg/ kg ITF2357 mildly suppressed
joint swelling as determined by 99mTc-
 uptake at days 1 and 2 (Figure 1A, B).
Since inhibition of HDAC suppressed
TNFα production in vitro as well as in
vivo, it is likely that the reduced joint
swelling seen after ITF2357 treatment is
due to lower TNFα levels. Indeed, when
the local cytokine production was deter-
mined, a 45% reduction of TNF produc-
tion was seen in mice treated with 10 mg/
kg ITF2357 (Table 1). In line with these
findings, SCW-induced joint swelling is
completely absent in TNFα gene deficient
mice or mice treated with neutralizing
anti-TNFα antibodies (28,30).
Induction of SCW arthritis results in a
dramatic suppression of chondrocyte
metabolic function as measured by the in-
corporation of radiolabeled 35S-sulphate
into the patellar cartilage. As an example,
an inhibition of chondrocyte proteoglycan
(PG)-synthesis of 44% is seen in Figure
1C. Oral treatment with 1 and 10 mg/kg
ITF2357 dose dependently reduced the
suppression of chondrocyte PG synthesis
compared with the control group (27%
and 13%, respectively, versus 44% in the
control group). It is known that inhibition
of chondrocyte PG synthesis due to joint
inflammation, progressively leads to se-
vere cartilage damage. IL-1β appears to be
the most potent cytokine studied to date
with respect to chondrocyte PG- synthesis.
Overexpression of IL-1β results in irre-
versible cartilage destruction (27). It is
likely that the same modulation of IL-1 by
HDACi as seen in other models of inflam-
mation accounts for the reduced inhibi-
tion of chondrocyte PG- synthesis seen
here, and hence in a protective effect
against cartilage catabolism during arthri-
tis. This was confirmed by the finding
that treatment with 1 mg/kg or 10 mg/kg
ITF2357 produced less IL-1β, namely 17%
and 62%, respectively,  compared with
SCW-control animals (Table 1). Interest-
ingly, other proinflammatory cytokines
(for example, IL-1α and IFNγ) including
arthritogenic ones such as IL-6 and IL-12
or chemo kines MIP-1α KC were dose de-
pendently inhibited by ITF2357, suggest-
ing a broad antiinflammatory effect for
the drug (Table 1).
In SCW-induced arthritis, influx of pre-
dominantly PMNs can be noted in the
joint cavity of inflamed joints (Figure 1D).
Figure 1E shows the cellular  influx at 
day 2 of SCW-induced arthritis and dem-
onstrates that treatment with ITF2357 
(10 mg/kg) reduces the number of in-
flammatory cells in the joint cavity. In
contrast, no protective effect was noted
on PG loss from the cartilage layers with
either 1mg/kg or 10mg/kg ITF 2357 as
measured by Safranin O staining. How-
ever, since inhibition of HDAC activity
results in protection against inhibition of
chondrocyte PG synthesis, the overall ef-
fect on cartilage of ITF2357 is beneficial to
the cartilage structure.




Since inhibition of HDAC activity by
ITF2357 resulted in amelioration of acute
joint inflammation and cartilage damage
(improved chondrocyte proteoglycan
synthesis) the effect of the drug was stud-
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Table 1. Protective effect of ITF2357 on acute joint inflammation and cartilage catabolism.
Inhibition (%) of synovial cytokine production after ITF2357 treatment
mg/kg TNFα IL-1β IL-1α IL-6 IFNγ IL-12 MIP-1α KC
1 –11.8 16.7 36. 7 –9.3 4.8 0.5 0.7 17.4
5 17.5 30.1 35.2 14.3 42.1 23.8 17.2 32.0
10 45.3 61.7 66.3 39.3 59.1 64.2 51.9 25.8
Joint inflammation was induced by injection of 25 μg SCW fragments into the right knee
joint of C57/Bl6 mice 2 h after ITF2357 had been supplied orally (n = 5 mice per group).
After 4 h, patellae with surrounding synovial tissue were isolated and cultured for 1 h at RT
in RPMI 1640 medium. Cytokines were determined by Luminex bead array system. Values
represent the reduction in cytokine production compared with vehicle control. A negative
value indicates induction of cytokines.
ied in arthritis models expressing severe
joint destruction (bone and cartilage),
namely murine type II collagen- induced
arthritis (CIA) and rat adjuvant–induced
arthritis (AA). Joint destruction is the
hallmark of RA and one of the main tar-
gets for targeted therapies in RA.
In the CIA model, ITF2357 was adminis-
tered either immediately after immuniza-
tion with CII/FCA (prophylactic treat-
ment) or 22 days after the induction of
arthritis (therapeutic treatment). As shown
in Figure 2A, 10 mg/kg ITF2357 given
prophylactically had a suppressive effect
on arthritis development (macroscopic
disease activity), when compared with ve-
hicle. Interestingly, a virtually identical ef-
fect was seen when ITF2357 (10 mg/kg)
was administered in the therapeutic regi-
men (Figure 2B). The beneficial effects of
ITF2357 treatments were demonstrated
further by histo pathology analysis of the
joint carried out on day 35. As seen in
Table 2, both inflammatory cell influx and
joint destruction were  decreased dramati-
cally after exposure to 10 mg/kg/day of
ITF2357, irrespective of the treatment
 regimen.
Since rat AA displays more severe
prominent bone destruction compared
with murine CIA, rats with AA were
treated with 5–50 mg/kg ITF25357. Pro-
phylactic treatment with 50 mg/kg/day
showed an optimal antiinflammatory ef-
fect when compared with vehicle control
(Figure 2C). This suppressive effect was
almost similar to leflunomide treatment
(positive control) and resulted in strong
reduction of bone pathology (data not
shown).
Several reports confirmed the above
findings that inhibition of HDAC
strongly reduced disease severity in
models of experimental arthritis (25). In
line with our results, prominent protec-
tion against bone destruction was seen
after treatment with HDACi (33).
BONE PROTECTIVE EFFECT OF ITF2357
Several preclinical studies showed that
HDACi, including ITF2357, protect against
severe bone destruction. TNFα and IL-1
are important cytokines that drive bone
erosion in arthritis as shown in transgenic
mice overexpressing human TNFα, where
bone destruction was a prominent feature,
and by blocking IL-1 receptors with anti-
bodies early in the disease, which pre-
vented bone loss. Furthermore, massive
bone destruction was strongly reduced in
mice transgenic for human TNFα but defi-
cient in IL-1 (34,35). The effect of ITF2357
on bone turnover was, therefore, studied
in a bone assay where bone destruction is
induced by either TNFα or IL-1β (36). Cal-
cium release from 5-day-old mouse cal-
varia was measured 48 hours after addi-
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Figure 2. ITF2357 ameliorates both murine CIA and rat AA. (A) Murine type II collagen-
 induced arthritis was induced according to standard procedures. DBA-1 mice were
treated orally with vehicle or ITF2357 at 1 and 10 mg/kg/day. Dexamethasone (0.25mg/kg)
was used as positive control (n = 10 mice per group). Treatment was started just after the
mice were immunized with CII/FCA (prophylactic). Mice were examined visually for arthri-
tis expression. Noted that ITF2357 showed a potent antiinflammatory effect at a dose of
10 mg/kg/day. (B) ITF2357 was administered orally at a dose of 10 mg/kg in a prophylac-
tic regimen (as in panel A) or starting on day 22 after arthritis induction (therapeutic regi-
men). (C) Rat adjuvant arthritis (AA) treated with ITF2357 (5 and 50 mg/kg). AA was in-
duced using a standard protocol. Rats (n = 8 per group) were treated for 21 d, starting
directly after immunization with FCA/MTB. Leflunomide (10 mg/kg/day) was used as posi-
tive control. Potent suppression of AA with both ITF2357 (50 mg/kg) and Leflunomide 
(10 mg/kg). Mann-Whitney U test was used for statistical analysis.
tion of the cytokines in the absence or the
presence of increasing amounts of the
drug. As expected, a much larger concen-
tration of TNFα was needed to induce the
same degree of bone resorption as that of
IL-1β (1 μg/mL versus 5 ng/mL) consis-
tent with the prominent role of the latter
on bone destruction as compared with the
former. ITF2357 strongly inhibited bone
resorption induced by either TNFα or
IL-1β (Figure 3A, B). The dose of ITF2357
needed for optimal inhibition was approx-
imately 100 nmol/L. Bone resorption in-
duced by the classic activators PGE2, 1,25
OH-Vit D3, parathyroid hormone or LPS
also was blocked by ITF2357 although
concentrations of about 1 μmol/L were
needed for a 50% reduction (data not
shown).
Recently, it was shown that HDACi in-
hibit osteoclastogenesis and bone resorp-
tion by suppressing the induction of c-Fos
by RANKL (37). In addition, HDACi in-
duce IFN-β and thereby suppress osteo-
clastogenesis and bone destruction (38). In
addition, HDACi are potent MMP in-
hibitors which are involved in both carti-
lage and bone destruction (39–41). Taken
together, these data indicate that HDACi
may be a future therapy for chronic joint
diseases, in which bone destruction is dif-
ficult to treat.
FINAL REMARKS
Collectively the data from the literature
and the results on ITF2357 presented here
demonstrate that HDACi have a strong
antiinflammatory and antidestructive ef-
fect in several models of arthritis. ITF2357,
in particular, suppressed both acute and
chronic arthritis. In the SCW model, joint
swelling, the inhibition of chondrocyte
proteoglycan synthesis and the influx of
inflammatory cells to the inflamed joints
were suppressed dose dependently by
oral treatment with the drug. TNFα and
IL-1β in the joint cavity also were reduced
by ITF2357. This is consistent with the
role played by the two cytokines in this
model where joint swelling and cell influx
are driven by TNFα, and IL-1β is crucial
in the inhibition of chondrocyte PG syn-
thesis. Inhibition of TNFα and IL-1β is not
the only mechanism by which ITF2357 ex-
erts its protective effect in the SCW-
model, since other proinflammatory cy-
tokines including arthritogenic IL6 and
IL12 and chemokines were downmodu-
lated equally by the drug (Table 1).
In addition to the suppressive effect in
the acute model of arthritis, ITF2357 and
other HDACi are protective in models of
chronic arthritis. Remarkably, the efficacy
seen upon administration of the drug be-
fore arthritis induction is comparable to
that obtained when the treatment begins
after the onset of the disease (25,33 and
Figure 2). Furthermore, as with the SCW
model, HDAC inhibition reduces bone
destruction in these models of chronic
arthritis (33 and Table 2; see Figure 2).
Inhibition of bone resorption also was
observed in vitro where ITF2357 sup-
pressed calcium release induced in
mouse calvaria by IL-1β or TNFα or
other stimuli (Figure 3). Thus, not only is
HDAC inhibition able to downregulate
the expression of proinflammatory
 cytokines, it also is repressing their de-
structive effects on the bone. This is con-
sistent with the results from LPS-induced
activation of human PBMC where
ITF2357, vorinostat and other HDACi
suppress monocyte/macrophage produc-
tion of TNFα, IL12, IL-1β, etc. and their
activity on lymphocytes (9).
One of the critical questions for the
treatment of human arthritic conditions
with HDACi is whether or not sufficient
circulating concentrations can be
achieved by safe doses of these drugs.
Approximately 500 patients with differ-
ent pathologies have been treated to date
with ITF2357. Safe doses range from 1.4
to 2.1 mg/kg/day. Owing to differences
in the metabolic and adsorption
processes, the Cmax and AUC values of a
dose of 1.0 mg/ kg/ day ITF2357 in hu-
mans (including children) corresponds to
25–30 and 40 mg/kg/day, respectively, in
rodents. Therefore the efficacious doses of
10 or 50 mg/kg/day seen here in the var-
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Table 2. Histopathology evaluation of the effect of givinostat administration (10 mg/kg) on
joint inflammation and tissue damages in the CIA model at day 28.
Necrotic and 
Periarticular Bone and Dilatation of inflammatory deposits 
Treatment score cartilage damage joint cavity in the joint cavity
Vehicle 2.08 1.50 1.25 1.75
Prophylactic 0.75 0.67 0.58 0.58
Therapeutic 0.83 0.42 0.33 0.50
Figure 3. IL-1β- or TNFα-induced bone re-
sorption is inhibited by ITF2357. (A) IL-1β-
 induced Ca-release using the standard
mouse calvaria assay. Bone resorption
assay (calcium release in 48 h) from 
5-day-old mouse calvaria (n = 5 per
group). ITF2357 was added in a dose-
range from 0 up to 1 μM. PGE2 served as
positive control. IL-1β at 5ng/mL. (B) Identi-
cal for TNFα- induced bone resorption.
TNFα at 1 μg/ mL. Mann-Whitney U test was
used for statistical analysis. *P < 0.001.
ious models of experimental arthritis are
consistent with a human use. Indeed, in a
clinical trial in juvenile idiopathic arthri-
tis (JIA), givinostat (ITF2357) was given
to children at 1.5 mg/kg (in two divided
doses) for 12 weeks (5). The drug was
well tolerated and the overall  arthritis
score was suppressed in these  children.
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